Evidence map›Paper›PMID 38240961›Full record

ArticleDrugs - real world outcomes2024

Risk of Major Congenital Malformations Associated with the Use of Japanese Traditional (Kampo) Medicine Containing Ephedra During the First Trimester of Pregnancy.

Aoi Noda, Taku Obara, Fumiko Matsuzaki, Satoko Suzuki, Ryutaro Arita, Minoru Ohsawa, Ryo Obara, Kei Morishita, Fumihiko Ueno, Genki Shinoda and 9 more

Open access · goldAbstract read
In one paragraph

Article in Drugs - real world outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Aoi NodaTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.ORCID http://orcid.org/0000-0002-7644-6848
Taku ObaraTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan. obara-t@hosp.tohoku.ac.jp.
Fumiko MatsuzakiTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Satoko SuzukiDepartment of Kampo and Integrative Medicine, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
Ryutaro AritaDepartment of Kampo and Integrative Medicine, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
Minoru OhsawaDepartment of Kampo and Integrative Medicine, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
Ryo ObaraDepartment of Molecular Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
Kei MorishitaDepartment of Molecular Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
Fumihiko UenoTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Genki ShinodaTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Masatsugu OruiTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Keiko MurakamiTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Mami IshikuroTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Akiko KikuchiDepartment of Kampo and Integrative Medicine, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
Shin TakayamaDepartment of Kampo and Integrative Medicine, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
Tadashi IshiiDepartment of Kampo and Integrative Medicine, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
Hiroshi KawameTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Shigeo KureTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Shinichi KuriyamaTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Tohoku University · JP

Funding

Japan Agency for Medical Research and Development JP17km0105001Japan Agency for Medical Research and Development JP21tm0124005Japan Agency for Medical Research and Development JP21tm0424601Japan Society for the Promotion of Science 23K14378
6 · The paper itself

Abstract

backgroundJapanese traditional (Kampo) medicines containing ephedra may be used to treat colds during pregnancy. There are reports that ephedrine, a component of ephedra, has a risk of teratogenicity; however, the evidence remains equivocal.

objectiveThis study aimed to evaluate the risk of major congenital malformations (MCMs) associated with exposure to Kampo medicines containing ephedra during the first trimester of pregnancy using the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study).

methodsTo 23,730 mother-infant pairs who participated in the TMM BirThree Cohort Study from July 2013 to March 2017, questionnaires in early and middle pregnancy were distributed approximately at weeks 12 and 26 of pregnancy, respectively. Infants' risk of MCMs in women who used Kampo medicines containing ephedra or acetaminophen during the first trimester was assessed, and the odds ratios (ORs) were estimated with unadjusted and adjusted analyses.

resultsAmong 20,879 women, acetaminophen and Kampo medicines containing ephedra were used in 665 (3.19%) and 376 (1.80%) women, respectively, in the first trimester. Among the infants born to the mothers who used acetaminophen or Kampo medicine containing ephedra during the first trimester, 11 (1.65%) and 8 (2.13%), respectively, had overall MCMs. OR of overall MCMs was higher in women who used Kampo medicines containing ephedra than in those who used acetaminophen in the first trimester (adjusted OR, 1.45; 95% confidence interval (CIs), 0.57-3.71); however, the difference was not statistically significant.

conclusionsIn this study, there was no statistically significant association between the use of Kampo medicines containing ephedra during the first trimester of pregnancy and the risk of MCMs. Although some point estimates of ORs exceeded 1.00, the absolute magnitude of any increased risks would be low.

Identifiers

PMID38240961
PMCPMC11176120
OpenAlexW4391023708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.